Comparison of bone mineral loss in prostate cancer patients who is receiving GnRH agonist and -plus anti-androgen agent
Study identifier:NIS-OKR-CAS-2010/1
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Comparison of bone mineral loss in prostate cancer patients who is receiving GnRH agonist and -plus anti-androgen agent
Medical condition
GnRH agonist alone vs. GnRH agonist plus anti-androgen combination treated prostate cancer patients
Phase
-
Healthy volunteers
No
Study drug
-
Sex
Male
Actual Enrollment
312
Study type
Observational
Age
50 Years +
Date
Study Start Date: 01 Apr 2011
Primary Completion Date: 01 Feb 2014
Study Completion Date: 01 Feb 2014
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Feb 2015 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| A Total of 250 prostate cancer patients receiving GnRH agonist | - |
| B Total of 250 prostate cancer patients receiving GnRH agonist plus anti-androgen agent | - |
Contacts
Investigators
Principal Investigator
Joon Woo Bahn
AstraZeneca Korea
